Yu WJ - Search Results

1

[Effectiveness analysis of HA based triple-drug regimen as induction chemotherapy in the treatment of acute myeloid leukemia and its relationship with karyotype].

Mi YC, Xue YP, Yu WJ, Liu SH, Zhao YZ, Meng QX, Bian SG, Wang JX. Mi YC, et al. Among authors: yu wj. Zhonghua Xue Ye Xue Za Zhi. 2005 Dec;26(12):705-9. Zhonghua Xue Ye Xue Za Zhi. 2005. PMID: 16620570 Chinese.

2

The Hsp90 inhibitor 17-allylamide-17-demethoxygeldanamycin induces apoptosis and differentiation of Kasumi-1 harboring the Asn822Lys KIT mutation and down-regulates KIT protein level.

Yu W, Rao Q, Wang M, Tian Z, Lin D, Liu X, Wang J. Yu W, et al. Leuk Res. 2006 May;30(5):575-82. doi: 10.1016/j.leukres.2005.08.028. Epub 2005 Oct 6. Leuk Res. 2006. PMID: 16213582

3

[The heat shock protein 90 inhibitor induces apoptosis and differentiation of Kasumi-1 and its mechanisms].

Yu WJ, Rao Q, Wang M, Tian Z, Liu XR, Lin D, Wang JX. Yu WJ, et al. Zhonghua Xue Ye Xue Za Zhi. 2005 Dec;26(12):728-31. Zhonghua Xue Ye Xue Za Zhi. 2005. PMID: 16620576 Chinese.

4

Therapeutic experience of adult acute myeloid leukemia in a single institution of China and its relationship with chromosome karyotype.

Mi Y, Xue Y, Yu W, Liu S, Zhao Y, Meng Q, Bian S, Wang J. Mi Y, et al. Leuk Lymphoma. 2008 Mar;49(3):524-30. doi: 10.1080/10428190701836852. Leuk Lymphoma. 2008. PMID: 18297530

5

[Study on signal transduction pathway in differentiation and apoptosis of leukemia cells induced by heat shock protein inhibitor].

Yu WJ, Rao Q, Wang M, Tian Z, Xu ZF, Wang JX. Yu WJ, et al. Zhonghua Xue Ye Xue Za Zhi. 2007 Oct;28(10):677-80. Zhonghua Xue Ye Xue Za Zhi. 2007. PMID: 18399173 Chinese.

6

[Analysis of chemotherapeutic results and prognostic factors of adult acute lymphoblastic leukemia].

Fu MW, Mi YC, Qiu LG, Yu WJ, Lin D, Bian SG, Wang JX. Fu MW, et al. Among authors: yu wj. Zhonghua Xue Ye Xue Za Zhi. 2008 Jul;29(7):435-40. Zhonghua Xue Ye Xue Za Zhi. 2008. PMID: 19035173 Chinese.

7

Intensive induction chemotherapy with regimen containing intermediate dose cytarabine in the treatment of de novo acute myeloid leukemia.

Liu J, Mi Y, Fu M, Yu W, Wang Y, Lin D, Bian S, Wang J. Liu J, et al. Am J Hematol. 2009 Jul;84(7):422-7. doi: 10.1002/ajh.21441. Am J Hematol. 2009. PMID: 19484734 Free article.

8

Heat shock protein 90 inhibition results in altered downstream signaling of mutant KIT and exerts synergistic effects on Kasumi-1 cells when combining with histone deacetylase inhibitor.

Yu W, Wang J, Jin J, Qian W, Qian J, Cheng Y, Wang L. Yu W, et al. Leuk Res. 2011 Sep;35(9):1212-8. doi: 10.1016/j.leukres.2011.05.014. Epub 2011 May 31. Leuk Res. 2011. PMID: 21632108

9

Homoharringtonine in combination with cytarabine and aclarubicin in the treatment of refractory/relapsed acute myeloid leukemia: a single-center experience.

Yu W, Mao L, Qian J, Qian W, Meng H, Mai W, Tong H, Tong Y, Jin J. Yu W, et al. Ann Hematol. 2013 Aug;92(8):1091-100. doi: 10.1007/s00277-013-1758-5. Epub 2013 Apr 18. Ann Hematol. 2013. PMID: 23595277 Clinical Trial.

10

Low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus idarubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia.

Jin J, Chen J, Suo S, Qian W, Meng H, Mai W, Tong H, Huang J, Yu W, Wei J, Lou Y. Jin J, et al. Leuk Lymphoma. 2015 Jun;56(6):1691-7. doi: 10.3109/10428194.2014.963074. Epub 2014 Nov 3. Leuk Lymphoma. 2015. PMID: 25257348

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

470 results

Search Page

Filters